PARSIPPANY, NJ, Oct 03, 2011 (MARKETWIRE via COMTEX) -- The Medicines Company (MDCO) announced today launch of a new twelve hour formulation for Cleviprex(R) (clevidipine) Injectable Emulsion, which ...
Credit: Getty Images. HTX-019 is a proprietary IV injectable emulsion formulation designed to directly deliver aprepitant, a substance P/NK1 receptor antagonist, as a 30-second IV injection. A New ...
An injectable emulsion containing two omega-3 fatty acids found in fish oil markedly reduced brain damage in newborn rodents after a disruption in the flow of oxygen to the brain near birth, a study ...
APONVIE, an aprepitant product, highlighted as the only FDA-approved IV formulation Neurokinin-1 (“NK-1”) antagonist indicated for the prevention of PONV in adults, with a long half-life and quicker ...
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced that it has received Abbreviated New Drug Application (“ANDA”) approval from ...
A novel omega-3 injectable emulsion reduces brain damage in newborn rodents experiencing lack of oxygen at delivery, a major cause of disability in human infants and children. An injectable emulsion ...
Foresee Pharmaceuticals, a Taiwan and US-based biopharmaceutical company, announces the positive safety review by the independent Data and Safety Monitoring Board for its Casppian phase 3 registration ...
The Medicines Company announced launch of a new twelve hour formulation for Cleviprex (clevidipine) injectable emulsion, which was approved by the US Food and Drug Administration (US FDA) in June 2011 ...
An injectable emulsion containing two omega-3 fatty acids found in fish oil markedly reduced brain damage in newborn rodents after a disruption in the flow of oxygen to the brain near birth, a study ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback